3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
8
Phase 3
2
Phase 1/2
1
Phase 1
1
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Conditions
Breast Neoplasms
2
Neoplasm Metastasis
1
Carcinoma
1
Interventions
Cisplatin
726
Carboplatin
609
Paclitaxel
579
Cyclophosphamide
516
Radiotherapy
511
Docetaxel
477
Fluorouracil
454
Gemcitabine
438
Doxorubicin
383
Capecitabine
362
Dexamethasone
328
Oxaliplatin
289
pembrolizumab
283
Leucovorin
283
Bevacizumab
275
Etoposide
272
Vincristine
270
Rituximab
246
Prednisone
223
Pemetrexed
217
Cytarabine
205
Drug Therapy
194
Trastuzumab
176
Irinotecan
174
Methotrexate
171
Lenalidomide
137
Nivolumab
136
Filgrastim
135
Epirubicin
129
Tamoxifen
128
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Interventional
×
etirinotecan pegol
×
Clear all
NCT02915744
2023-04-14
ATTAIN
Nektar Therapeutics
Phase 3
Completed
178 enrolled
37 charts
NCT01492101
2021-06-01
BEACON
Nektar Therapeutics
Phase 3
Completed
852 enrolled
21 charts